Slide 1: Hemostemix Inc.
Hemostemix Inc. TSXV:HEM OTCQB:HMTXF FSE:2VF0
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward looking statements that reflect management’s Actual results, performance and achievement(s) could differ materially from that expectations regarding the future growth and results of operational performance expressed in, or implied by, any
Slide 3: Saving a Limb is Saving a Life!
T h r e e Q u e s t i o n s : 1 . D o e s i t w o r k ? 2 . C o m m e r c i a l i z a t i o n ? 3 . E x i t Va l u a t i o n ? Saving a Limb is Saving a Life! Whereas the CLTI five-year mortality is 50%, the Universities of Toronto and British Columbia presented: 83% of patients followed in the Phas
Slide 4: Safe, Efficacious, Clinically Relevant
I T W O R K S : 11 P e e r R e v i e w e d P u b l i c a t i o n s Safe, Efficacious, Clinically Relevant Mutiranga et al J Med Assoc of Henderson et al, Szabó GV, et al, Schubart et al, Tresukosol et al, Chaithiraphan et al, Arom et al, J Biomedical Thailand, 2009 Mar Cytotherapy. Stem Cell Res The
Slide 5: Production Agreement & Equity Investment - Supply
PAT H T O M A R K E T Production Agreement & Equity Investment - Supply CMO PRODUCTION AGREEMENT 15 YEAR AGREEMENT WITH PUERTO RICO Fully funded two-year production agreement that includes 23 Act 60 legislation generates 50% cash back of all current and ACP-01 Therapy. Each 20 patients per month gen
Slide 6: Treatments – Canada, The Bahamas, Florida
PAT H T O M A R K E T Treatments – Canada, The Bahamas, Florida Sales of ACP for no-option patient treatments We are purchasing Invasive Cardiology To-date, seven clinical trial sites have is through clinicians who have legal pathways Practice in Florida that enables the capacity to treat 336 Hemost
Slide 7: Key Process Steps with Treatment on Day 7
PROCESS Key Process Steps with Treatment on Day 7 ACP-01 (patient’s DNA) scales and ships in 3 x 10 cc ready to use syringes, to physicians globally. DAY 1 DAY 3 DAY 5 DAY 7 Blood collection Culturing and Quality Control release tests Administration of cells to and shipping differentiation of cells
Slide 8: Autologous Regenerative Therapeutic Competitors
COMPETITORS Autologous Regenerative Therapeutic Competitors Company Indications Source Phase Ischemic Heart Chronic Limb Chronic Limb | || ||| Disease Threatening Ischemia Threatening Ischemia Hemostemix Peripheral Blood1 BioCardia Bone Marrow2 Life Cells3 Acellular Dermal Matrices3 BioGen Cells Per
Slide 9: Historical Event Timeline
TIMELINE Historical Event Timeline 3rd Heart Study 106 Subject ICH World Economic Retrospective Forum Technology PHASE 1 91st Patent Heart Study Pioneer Award CLI Study published issued Published 2003 2005 2006 2009 2013 2020 2022 2023 Hemostemix PHASE 1 PHASE 2 Founded 24 subject 1st Heart 2nd CLI
Slide 10: Capital Table
PROFORMA Capital Table Hemostemix Inc. - Proforma Cap Table (Sept 30, 2025) Shares 183,706,725 Notes: 1. CD2 – 5-yr secured (1st position), due April-2027, Warrants @ $0.14 101,791,533 interest of 8% p.a. payable in shares, converts at $0.175 per share. Options. @$0.27 18,161,694 2. Warrants – Weigh
Slide 11: Use of Funds
USE OF FUNDS Cash Use - Manufacturing and Required Operating Costs Year 1 Year 2 Year 3 Year 4 Year 5 Use of Manufacturing Facility - (1 Clean Rm with 2 shifts; + working lab) Manufacturing - Costs+Staffing (add 2nd shift in 1yr-Q3) $1,591 $953 $1,053 $1,310 $1,053 $1,310 $1,053 $1,310 $1,053 $1,310
Slide 12: Precision Healthcare Fund
Precision Healthcare Fund A Special Purpose Vehicle for Discounted Access to Hemostemix Regenerative Medicine Growth Bulk Purchase of Therapeutic Convertible Debentures Issued by Hemostemix Inc. (TSXV: HEM)
Slide 13: Capital Raise & Use of Funds
Capital Raise & Use of Funds • Total Raise: $4,166,667 (Class B Shares) @ $1 each • Purchases 100 TCDs • Face Value: $5,000,000 • Purchase Price: $4,000,000 (20% discount) • Up to 4% Commission of funds raised: $166,667
Slide 14: Sources of Return
Sources of Return • 6% annual interest on $5,000,000 face value ($300,000/year) • Capital recycling through repeated TCD purchases of 1,000 • Realization of embedded 20% discount - $1,000,000 - on each 100 TCDs • The contractual right to repeat the purchase process 10 X from your investment • $4,000
Slide 15: What Are TCDs Therapeutic Convertible Debentures?
What Are TCDs Therapeutic Convertible Debentures? • 5-year unsecured debenture • $50,000 face value • Purchased wholesale in quantities of up to 100 at $40,000 • Convertible into: • ACP-01 therapeutic treatment batch, or • $50,000 of Hemostemix common shares
Slide 16: Fund Structure & Governance
Fund Structure & Governance • Private Canadian company - <50 shareholders • Class A - Founders: 11% ownership: 100 votes/share • Class B - Investors: 89% ownership: 1 vote/share • Investors hold majority economics while • Founders direct the strategy
Slide 17: Fees & Profit Participation
Fees & Profit Participation • Class B (Your) Participation: • 80% of returns between 10%–25% ROI • 70% of returns above 25% ROI • Founders Participation • 20% of returns between 10%–25% ROI • 30% of returns above 25% ROI • Administration: ~2% • Tax leakage estimate: ~1%
Slide 18: TCD Capital Reinvestment Assumptions
TCD Capital Reinvestment Assumptions Projected Years 1 2 3 4 5 Total Average TCDs 100 150 200 250 300 1,000 Sold ROI % 23.7 32.1 40.4 48.7 57 201.8 40.37 ROI, in $989 $1,336 $1,682 $2,029 $2,375 $8,410 $1,000
Slide 19: Use of Funds at Hemostemix
Use of Funds at Hemostemix • ACP-01 manufacturing via third-party contract manufacturing • Commercial rollout • Marketing • Advertising • Sales • General corporate purposes, including • Acquisitions of private medical practices • $40 Million non dilutive financing of the Company over 5 years
Slide 20: Why This Structure Works
Why This Structure Works • Discount-protected entry into autologous ACP-01 stem cell treatment sales • Florida legislation permits commercial sales to treat Pain under SB 1768 • The Bahamas permits all treatments, including Phase 1 trial participants • Canada permits treatment of foreigners under Sp
Slide 21: Exits & Comparables
E X I T S & C O M PA R A B L E S Life Sciences Investment ’24: $191 B; ’25: $72 B ’24 M&A: 6 deals $2.4 B; ’25 M&A: $240 B Bristol Myers $13.8 Billion Cash for Myocardia. Compare Hemostemix? Myocardia's Results (Lancet) ACP-01 Results (Stem Cell Research & Therapy) 251 (59%) were enrolled and random
Slide 22: Key Takeaways
SUMMARY Key Takeaways ACP is a break-through treatment for cardiovascular diseases: ACP is effective, and because it is sourced from the patient's angina, dilated and ischemic cardiomyopathy and CLTI, PAD, blood and cultured in the patient's serum, It is completely Vascular Dementia. autologous and
Slide 23: Thank You! Get in Touch!
T S X V: H E M OTCQB:HMTXF FSE:2VF0 Thank You! Get in Touch! Thomas Smeenk, CEO Cell: +1-905-580-4170 TSmeenk@Hemostemix.com 12 22